Annovis Bio vs ProMIS Neurosciences
ANVS and PMN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ANVS and PMN compare
Annovis Bio is the larger company, worth 1.3 times as much as ProMIS Neurosciences ($39.5M against $29.5M).
ProMIS Neurosciences scores higher on the StockData Score (6 against 4 for Annovis Bio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ANVS | PMN |
|---|---|---|
| Size and price | ||
| Market cap | $39.5M | $29.5M |
| Share price | $0.926 | $3.29 |
| Change, 1 year | −61.9% | −67.9% |
| Change, 5 years | −96.6% | −98.3% |
| Beta (5Y) | 1.95 | 0.55 |
| Employees | 8 | 30K |
| StockData Score | ||
| Total score | 4 | 6 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 4 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | – | 0.7× |
| Profitability | ||
| Return on equity | – | −152% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Current ratio | – | 8.83 |
| Altman Z-score | −86.45 | −3.18 (better) |
| Piotroski F-score | 3 (better) | 1 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 25.5% | 71.4% |
| Held by insiders | 23.1% | – |
| Insider net buying, 12 months | $6.8M | $8.9M (better) |
| Short interest, % of float | 16.3% | – |
Go deeper
- ANVS stock overview
- ANVS income statement
- ANVS valuation and score
- PMN stock overview
- PMN income statement
- PMN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.